Lipoprotein(a) levels are largely determined by genetics, with 70-90% of variation inherited. Higher Lp(a) levels correlate with an increased risk of heart attacks, strokes, and aortic valve disease. Most commonly used cholesterol-lowering medications, including statins, do not reduce Lp(a). However, newer drugs like PCSK9 inhibitors can lower Lp(a) by 15-30%.

Mindfulness training also plays a role in heart health. Research shows that daily mindfulness practice can lead to measurable improvements in cardiovascular health within just eight weeks. The therapeutic dose linked with blood pressure improvements involves daily practice reinforced by weekly sessions.

Regular consumption of pistachios has shown benefits as well. Studies indicate that eating pistachios can lead to lower LDL cholesterol and blood pressure. A handful provides 174 calories and 6.1 grams of protein.

The evolving understanding of lipoprotein(a) is crucial for future cardiovascular strategies. Currently, Lp(a) isn’t included in routine cholesterol tests, and there’s little we can do about it.

The impact of mindfulness on heart health is promising. Rosalba Hernandez stated, “The therapeutic dose that was most consistently linked with improvements in blood pressure, inflammation and endothelial function was daily practice reinforced by weekly sessions over eight to 12-week periods.” Mindfulness helps regulate the body effectively.

The integration of new treatments for lipoprotein(a) alongside lifestyle changes like mindfulness and diet could redefine cardiovascular disease management. Multiple clinical trials have found that regularly eating pistachios can lead to lower total cholesterol and LDL ‘bad’ cholesterol.

The post Heart health innovations target lipoprotein(a) appeared first on News Casino.

Lp(a) was first discovered in 1963. Research shows that individuals with high levels of Lp(a) have more than double the risk of heart attack compared to those without elevated levels. Alarmingly, an estimated one in five people worldwide has elevated Lp(a). Despite this, less than 1% of adults were tested for it in the U.S. in 2024.

Recent developments have changed the landscape. Novartis, Amgen, and Eli Lilly are now conducting late-stage trials to evaluate whether drugs that lower Lp(a) can protect against heart attacks. Novartis’ drug pelacarsen aims specifically to reduce Lp(a) levels. In tests, these companies have shown their experimental drugs can cut Lp(a) by more than 80%.

These promising results have caught the attention of experts. Dr. Steve Nissen remarked, “We thought raising HDL would be beneficial and that didn’t work, so I think we have to keep an open mind.” The potential for these drugs is substantial—experts predict annual sales could reach $5.6 billion by 2032 if successful.

However, uncertainties remain. The exact threshold of Lp(a) reduction necessary to prevent heart attacks is still unknown. Additionally, the timeline for results from Novartis’ trial has faced delays due to slower-than-expected occurrences of heart attacks.

Experts like Jay Bradner emphasize the importance of this research: “The clarity of the signal from population genetics and the encouraging signs from earlier trials render this a very smart bet.” Asad Haider added that Novartis’ trial will be crucial for shaping perceptions about this emerging area in cardiology.

This focus on Lp(a) represents a paradigm shift in how cardiovascular disease may be treated in the future. If these drugs prove effective, they could change treatment protocols significantly and save countless lives.

The next key data point is expected from Lilly’s Phase 3 trial of lepodisiran in 2029. Until then, the medical community watches closely as these developments unfold.

The post Cholesterol: Pharmaceutical Companies Bet on Lp(a) for Heart Drugs appeared first on News Casino.